CClinicalTrials.gg
CompletedNCT04098458Updated Mar 22, 2021Results posted

Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC

An interventional study of NDURE in Squamous Cell Carcinoma of Head and Neck, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Head and neck cancer squamous cell carcinoma (HNSCC) is a disease with poor survival, especially for African Americans, despite intense treatment including surgery, radiation, and chemotherapy. Delays between surgery and the start of postoperative radiation therapy (PORT) are common, cause excess mortality, and contribute to worse survival in African Americans. Our research team has developed NDURE (Navigation for Disparities and Untimely Radiation thErapy), a novel theory-based patient navigation (PN) intervention to decrease delays and racial disparities starting PORT. In this single-site, open label, single-arm trial, adults with surgically-managed, locally advanced HNSCC, will be enrolled in NDURE to assess the feasibility and acceptability of NDURE as a novel approach to decreasing delays and racial disparities starting PORT after surgery for HNSCC. The investigators will collect information about the accrual rate and NDURE completion rate. Participants will also complete validated questionnaires at baseline and post-intervention to evaluate the feasibility of outcome assessment for NDURE. Post-intervention, patients and providers will undergo interviews to obtain in-depth understanding of the content, format, timing, and delivery of NDURE to optimize the intervention in preparation for a future multi-site study. NDURE could provide the first effective intervention to improve the delivery of timely, equitable PORT after HNSCC surgery, thereby improving survival for patients with HNSCC, decreasing racial disparities in mortality, and developing new standards of clinical care.

Read the detailed description

Design: The study design is a single-site, single-arm, trial of NDURE (Navigation for Disparities and Untimely Radiation thErapy) to assess the feasibility and acceptability of this patient navigation (PN) intervention to decrease delays and racial disparities starting postoperative radiation therapy (PORT) after surgery for HNSCC.

Following screening and informed consent, sociodemographic and oncologic will be prospectively gathered about participants from validated questionnaires and the electronic medical record (EMR). Participants will undergo 3 sessions of NDURE. Measures of feasibility (enrollment, dropout, missed PN encounters, navigator caseload, and time allocation) will be assessed during delivery of NDURE. Questionnaires assessing symptom burden and health-related beliefs will be collected at baseline and post-treatment to assess the feasibility of data collection procedures and monitor completion rates. Following completion of NDURE, patients with HNSCC will complete validated measures of acceptability related to satisfaction with PN. Post-NDURE qualitative work with patients and providers will help refine the intervention

Treatment Allocation: Participants will be enrolled into NDURE

Delivery of intervention: NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels. NDURE consists of 6 key functions including (1) Improve patient knowledge about Guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care.

Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each. The three NDURE sessions coincide with the pre-surgical consult, hospital discharge, and first postoperative visit, time points chosen to facilitate case identification and coordination across care transitions. During each NDURE session, the navigator delivers patient education and creates or updates the PORT Care Plan. Referral tracking and follow-up occurs through asynchronous contact between the navigator, patient, and healthcare organizations between NDURE sessions.

The sample size justification for this single-arm study is based on the primary feasibility endpoints of NDURE accrual and completion. In the randomized controlled trial (RCT) of NDURE (NCT04030130), the investigators plan to enroll 60% of eligible patients. The investigators expect similar accrual in this feasibility study and therefore, accruing to NDURE will be considered feasible if at least 15 of 25 eligible subjects enroll. Our sample size was selected to provide a small probability of having an observed accrual rate of at least 60% when the true accrual probability is actually less than 60%. For example, if the true accrual probability for our proposed design is 45% (35%), the probability of enrolling 15 or more of 25 eligible subjects is only 10% (1%). Additionally, the investigators target an NDURE completion rate ≥85%. That is to say, NDURE is feasible if at least 13 of the 15 subjects enrolled complete all three in-person NDURE sessions. Accordingly, the sample size for the single-arm study was selected to provide a small probability of having an observed completion rate of at least 85% when the true completion probability of the intervention is actually less than 85%. For example, if the true completion probability for our proposed design is 70% (60%), the probability that 13 or more of the 15 enrolled patients complete all three in-person NDURE sessions is 13% (3%). Therefore, the probability of falsely declaring NDURE feasible is reasonably controlled based on this sample size.

Statistical Methods of Analysis: This aim is descriptive, and the statistical analysis focuses on characterizing the feasibility and acceptability of NDURE. To examine patterns and characterize sociodemographic, oncologic, and symptom burden variables, the investigators will construct graphical displays and descriptive statistics (e.g. frequencies and percent for categorical variables and mean, median, standard deviation, and range for continuous variables). Feasibility measures for study accrual rate will evaluate the proportion and frequency of eligible patients who accrue (overall, white, and African American). Given its pilot nature, the study is not designed to evaluate racial differences in accrual, although reasons for study decline will be collected, analyzed for each racial subgroup, and used to refine recruitment. NDURE completion rate will be analyzed as 1) the percentage of enrolled patients who attend all three in-person NDURE sessions and 2) the proportion of three in-person NDURE sessions that are completed. For navigator caseload, the investigators will consider the frequency of simultaneous cases navigated. Navigator time allocation for direct and indirect time, as well as patient-report measures of satisfaction with navigation will be summarized as described above for continuous data. Study questionnaire completion rate will be calculated as the proportion of pre- and post-intervention questionnaires (n=5 each) completed. Qualitative data will be analyzed using established team codebooks and focus on the content, format, delivery, and timing of NDURE. Qualitative analysis of semi-structured interviews with patients and providers following the pilot will be analyzed using established codebooks from the study team for evaluating the feasibility and acceptability of clinic-based interventions with a focus on the content, format, delivery, and timing of NDURE.

02

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
03

In context

Squamous Cell Carcinoma of Head and Neck

1,680 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 539 are open to participants now.

This study's enrollment of 18 is below the median of 49 across 1,432 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 852 studies on the registry; 165 are open to participants now.

Of its 128 completed or terminated interventional studies of FDA-regulated products, 101 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Patient and disease characteristics

  1. Age > 18 years at the time of screening
  2. Histologically or pathologically confirmed invasive SCC (or histologic variant) of the oral cavity, oropharynx (p16 positive, negative, or unknown), hypopharynx, larynx, unknown primary, paranasal sinuses, or nasal cavity.

    a. In situations in which the patient fulfills all other inclusion criteria but the biopsy shows SCC in-situ or moderate/severe dysplasia (without definitive evidence of invasive SCC), but the patient is scheduled to undergo curative intent surgery by the treating oncologic surgeon due to clinical suspicion of invasive SCC, the diagnosis of SCC-in situ or moderate/severe dysplasia is sufficient to full the pathologic diagnosis enrollment criterion.

  3. American Joint Committee on Cancer (AJCC) clinical stage grouping III-IV (8th edition) for patients with SCC of the oral cavity, p16-negative oropharynx, hypopharynx, larynx, paranasal sinuses, and nasal cavity; or AJCC clinical stage grouping III-IV (7th edition) for patients with p16-positive SCC of the oropharynx or unknown primary.

    1. At screening, AJCC clinical stage grouping should be determined based on a combination of physical exam, diagnostic evaluation with cross sectional imaging of the neck (computerized tomography (CT) and/or magnetic resonance imaging (MRI)) and/or 18-F-fluoro-deoxyglucose positron emission tomography (FDG PET) CT within 30 days
    2. In situations in which the patient fulfills all other inclusion criteria but the biopsy shows SCC in-situ or moderate/severe dysplasia (without definitive evidence of invasive SCC), but would otherwise have an appropriate clinical stage grouping as defined in criterion 5, the diagnosis of SCC-in situ or moderate/severe dysplasia is sufficient to full the staging enrollment criterion.
  4. No prior exposure to radiation therapy, with or without concurrent chemotherapy, for treatment of HNSCC in the definitive or adjuvant therapy settings

    Surgery and adjuvant therapy eligibility

  5. Plan for curative intent surgery at MUSC

    a. At screening, plan for curative intent surgical resection of the HNSCC at MUSC must be deemed likely by the treating surgeon and/or multidisciplinary tumor board, which must include a fellowship-trained head and neck oncologic surgeon

  6. Plan for PORT (at MUSC or non-MUSC) with or without concurrent chemotherapy following curative intent surgery a. At screening, plan for adjuvant therapy following curative intent surgical resection of the HNSCC at MUSC must be deemed likely by the treating surgeon and/or multidisciplinary tumor board, which must include a fellowship-trained head and neck oncologic surgeon, based on the clinical expectation of at least one of the following adverse features on final pathologic evaluation: extranodal extension (ENE), pathologic T3 or T4 primary, N2 or N3 nodal disease, nodal disease in levels IV or V, perineural invasion (PNI), or lymphovascular invasion (LVI)

Exclusion criteria

Exclusion Criteria:

  1. Self-identified Hispanic ethnicity
  2. Presence of cognitive impairment that precludes participation
  3. Failure to undergo curative intent surgery at MUSC
  4. Lack of indication for PORT (with or without concurrent chemotherapy) per National Comprehensive Cancer Network (NCCN) Guidelines based on the presence of at least one of the following adverse features on final pathologic evaluation: ENE, positive margin, pathologic stage T3 or T4 primary, pathologic stage N2 or N3 nodal disease, nodal disease in levels IV or V, perineurial invasion, or lymphovascular invasion
  5. Synchronous untreated malignancy
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    NDURE

    NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.

    Behavioral: NDURE

Interventions

  • BehavioralNDURE

    NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.

06

What researchers measure

Primary outcomes

  1. Percent of Eligible Participants Who Accrue to NDURE

    Percent of eligible participants who accrue to NDURE, defined as a participant who meets all inclusion criteria and no exclusion criteria

    Time frame: 5 months

Secondary outcomes

  1. Percent of Participants Who Complete the NDURE Intervention and Study Measures

    Completion of the baseline assessment, at least two (of 3) NDURE intervention sessions, and the end of study assessment

    Time frame: 5 months

  2. Satisfaction With the Interpersonal Relationship With the Navigator (PSN-I) Scale Score

    The PSN-I measures the satisfaction with the interpersonal relationship with the patient navigator. The PSN-I score is defined as the total score of this 9-item scale. The total score ranges from 9 (minimum) to 45 (maximum); higher scores represent a better outcome (greater satisfaction with the interpersonal relationship with the navigator).

    Time frame: Post-intervention (3 months)

  3. Navigator Caseload

    The number of simultaneous cases (on-trial participants) being navigated by the NDURE navigator

    Time frame: 5 months

  4. Navigator Time Allocation (Direct)

    The time (in minutes), that the NDURE navigator spends directly interacting with the patient to identify and address barriers to timely, equitable postoperative radiation therapy.

    Time frame: 3 months

  5. Navigator Time Allocation (Indirect)

    The time (in minutes), that the navigator spends generating and enacting each Barrier Reduction Plan that is not directly interacting with the patient

    Time frame: 3 months

  6. Navigator Time Allocation (Total)

    The time (in minutes), that the NDURE navigator spends directly or indirectly interacting with the patient to identify and address barriers to timely, equitable postoperative radiation therapy

    Time frame: 3 months

  7. Percent of Patients With a Delay Starting Post-Operative Radiation Treatment

    Percent of patients who start PORT \>6 weeks after surgery. Initiation of postoperative PORT \> 6 weeks after surgery is defined as more than 42 calendar days from the time of the definitive surgical resection to the initiation of radiation therapy. In situations in which the surgical management of the primary tumor and the neck are staged (i.e. occur on two different calendar days), the date of the surgery for the primary tumor will be used. In situations in which an additional surgical resection is required (e.g. re-resection of positive margins to clear residual disease), the date of the earlier (i.e. attempted definitive) surgical procedure will be used to determine the target start date for PORT.

    Time frame: 6 weeks

  8. Percent Difference in PORT Delay Between White and Black Patients With Head and Neck Cancer

    The difference in the rate of initiation of PORT \> 6 weeks after surgery between white and black patients with head and neck cancer (i.e., percent difference = percent of white patients with PORT delay minus percent of black patients with PORT delay)

    Time frame: 6 weeks

  9. NDURE Program Evaluation Scale Score: Utility of Sessions With the Navigator

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The sessions meeting with the navigator were useful to help prevent a delay starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  10. NDURE Program Evaluation Scale Score: Timeline of Activities

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The timeline of activities for starting radiation after surgery was useful." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  11. NDURE Program Evaluation Scale Score: Helpful in Identifying Challenges Starting Radiation Therapy

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The navigator was helpful in identifying my specific challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  12. NDURE Program Evaluation Scale Score: Helpful in Coming up With a Plan to Solve Challenges Starting Radiation

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The navigator was helpful in coming up with a plan to solve my specific challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  13. NDURE Program Evaluation Scale Score: Helpful in Solving Challenges Starting Radiation

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The navigator was helpful in solving my specific challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  14. NDURE Program Evaluation Scale Score: Material From Navigator Was Relevant

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "he material that I received from the navigator was relevant in helping me address my challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  15. NDURE Program Evaluation Scale Score: Timing of Program

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The timing of the program starting at my surgical consultation (before surgery) worked well for me." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  16. NDURE Program Evaluation Scale Score: Method of Delivery

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The method of meeting with the navigator to ensure timely head and neck cancer care (face to face) worked well for me." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  17. NDURE Program Evaluation Scale Score: Number of Sessions

    The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The number of sessions with the navigator (at least 3) worked well for me." Higher scores represent higher levels of agreement.

    Time frame: 3 months

  18. NDURE Program Evaluation Scale Score: Overall Satisfaction

    The study-specific program evaluation scale asks participants to rate their satisfaction with the NDURE program on a scale of 1-5; higher scores represent higher levels of satisfaction.

    Time frame: 3 months

  19. NDURE Program Evaluation Scale Score: Likelihood to Recommend

    The study-specific program evaluation scale asks participants to rate their likelihood to recommend this program to someone else with head and neck cancer on a scale of 1-5; higher scores represent a greater likelihood of recommending NDURE.

    Time frame: 3 months

07

Results

Posted Mar 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneNDURE
Started18
Completed14
Not completed4
Withdrew: Death1
Withdrew: Did not meet study inclusion criteria3

Outcome measures

PrimaryPercent of Eligible Participants Who Accrue to NDURE

Percent of eligible participants who accrue to NDURE, defined as a participant who meets all inclusion criteria and no exclusion criteria

Time frame:
5 months
Reported as:
Count of participants · Participants
Percent of Eligible Participants Who Accrue to NDURE
ParticipantsNDURE
Percent of Eligible Participants Who Accrue to NDURE15
SecondaryPercent of Participants Who Complete the NDURE Intervention and Study Measures

Completion of the baseline assessment, at least two (of 3) NDURE intervention sessions, and the end of study assessment

Time frame:
5 months
Reported as:
Count of participants · Participants
Percent of Participants Who Complete the NDURE Intervention and Study Measures
ParticipantsNDURE
Percent of Participants Who Complete the NDURE Intervention and Study Measures14
SecondarySatisfaction With the Interpersonal Relationship With the Navigator (PSN-I) Scale Score

The PSN-I measures the satisfaction with the interpersonal relationship with the patient navigator. The PSN-I score is defined as the total score of this 9-item scale. The total score ranges from 9 (minimum) to 45 (maximum); higher scores represent a better outcome (greater satisfaction with the interpersonal relationship with the navigator).

Time frame:
Post-intervention (3 months)
Reported as:
Mean · score on a scale
Satisfaction With the Interpersonal Relationship With the Navigator (PSN-I) Scale Score
score on a scaleNDURE
Satisfaction With the Interpersonal Relationship With the Navigator (PSN-I) Scale Score38 ± 2.9
SecondaryNavigator Caseload

The number of simultaneous cases (on-trial participants) being navigated by the NDURE navigator

Time frame:
5 months
Reported as:
Mean · simultaneous cases
Navigator Caseload
simultaneous casesNDURE
Navigator Caseload3.5 (1 to 5)
SecondaryNavigator Time Allocation (Direct)

The time (in minutes), that the NDURE navigator spends directly interacting with the patient to identify and address barriers to timely, equitable postoperative radiation therapy.

Time frame:
3 months
Reported as:
Mean · minutes per patient
Navigator Time Allocation (Direct)
minutes per patientNDURE
Navigator Time Allocation (Direct)96 (90 to 135)
SecondaryNavigator Time Allocation (Indirect)

The time (in minutes), that the navigator spends generating and enacting each Barrier Reduction Plan that is not directly interacting with the patient

Time frame:
3 months
Reported as:
Mean · minutes/patient
Navigator Time Allocation (Indirect)
minutes/patientNDURE
Navigator Time Allocation (Indirect)135 (120 to 195)
SecondaryNavigator Time Allocation (Total)

The time (in minutes), that the NDURE navigator spends directly or indirectly interacting with the patient to identify and address barriers to timely, equitable postoperative radiation therapy

Time frame:
3 months
Reported as:
Mean · minutes/patient
Navigator Time Allocation (Total)
minutes/patientNDURE
Navigator Time Allocation (Total)231 (210 to 330)
SecondaryPercent of Patients With a Delay Starting Post-Operative Radiation Treatment

Percent of patients who start PORT \>6 weeks after surgery. Initiation of postoperative PORT \> 6 weeks after surgery is defined as more than 42 calendar days from the time of the definitive surgical resection to the initiation of radiation therapy. In situations in which the surgical management of the primary tumor and the neck are staged (i.e. occur on two different calendar days), the date of the surgery for the primary tumor will be used. In situations in which an additional surgical resection is required (e.g. re-resection of positive margins to clear residual disease), the date of the earlier (i.e. attempted definitive) surgical procedure will be used to determine the target start date for PORT.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Percent of Patients With a Delay Starting Post-Operative Radiation Treatment
ParticipantsNDURE
Percent of Patients With a Delay Starting Post-Operative Radiation Treatment2
SecondaryPercent Difference in PORT Delay Between White and Black Patients With Head and Neck Cancer

The difference in the rate of initiation of PORT \> 6 weeks after surgery between white and black patients with head and neck cancer (i.e., percent difference = percent of white patients with PORT delay minus percent of black patients with PORT delay)

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Percent Difference in PORT Delay Between White and Black Patients With Head and Neck Cancer
percentage of participantsNDURE
Percent Difference in PORT Delay Between White and Black Patients With Head and Neck Cancer14.2
SecondaryNDURE Program Evaluation Scale Score: Utility of Sessions With the Navigator

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The sessions meeting with the navigator were useful to help prevent a delay starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Utility of Sessions With the Navigator
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Utility of Sessions With the Navigator4.79 ± 0.58
SecondaryNDURE Program Evaluation Scale Score: Timeline of Activities

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The timeline of activities for starting radiation after surgery was useful." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Timeline of Activities
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Timeline of Activities4.85 ± 0.38
SecondaryNDURE Program Evaluation Scale Score: Helpful in Identifying Challenges Starting Radiation Therapy

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The navigator was helpful in identifying my specific challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · units on a scale
NDURE Program Evaluation Scale Score: Helpful in Identifying Challenges Starting Radiation Therapy
units on a scaleNDURE
NDURE Program Evaluation Scale Score: Helpful in Identifying Challenges Starting Radiation Therapy4.79 ± 0.58
SecondaryNDURE Program Evaluation Scale Score: Helpful in Coming up With a Plan to Solve Challenges Starting Radiation

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The navigator was helpful in coming up with a plan to solve my specific challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Helpful in Coming up With a Plan to Solve Challenges Starting Radiation
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Helpful in Coming up With a Plan to Solve Challenges Starting Radiation4.85 ± 0.38
SecondaryNDURE Program Evaluation Scale Score: Helpful in Solving Challenges Starting Radiation

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The navigator was helpful in solving my specific challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Helpful in Solving Challenges Starting Radiation
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Helpful in Solving Challenges Starting Radiation4.69 ± 0.48
SecondaryNDURE Program Evaluation Scale Score: Material From Navigator Was Relevant

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "he material that I received from the navigator was relevant in helping me address my challenges starting radiation therapy after surgery." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Material From Navigator Was Relevant
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Material From Navigator Was Relevant4.64 ± 0.63
SecondaryNDURE Program Evaluation Scale Score: Timing of Program

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The timing of the program starting at my surgical consultation (before surgery) worked well for me." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Timing of Program
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Timing of Program4.85 ± 0.38
SecondaryNDURE Program Evaluation Scale Score: Method of Delivery

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The method of meeting with the navigator to ensure timely head and neck cancer care (face to face) worked well for me." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Method of Delivery
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Method of Delivery5.0 ± 0.0
SecondaryNDURE Program Evaluation Scale Score: Number of Sessions

The study-specific program evaluation scale asks participants to rate their agreement with the following statement on a scale of 1-5: "The number of sessions with the navigator (at least 3) worked well for me." Higher scores represent higher levels of agreement.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Number of Sessions
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Number of Sessions4.43 ± 1.09
SecondaryNDURE Program Evaluation Scale Score: Overall Satisfaction

The study-specific program evaluation scale asks participants to rate their satisfaction with the NDURE program on a scale of 1-5; higher scores represent higher levels of satisfaction.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Overall Satisfaction
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Overall Satisfaction4.92 ± 0.28
SecondaryNDURE Program Evaluation Scale Score: Likelihood to Recommend

The study-specific program evaluation scale asks participants to rate their likelihood to recommend this program to someone else with head and neck cancer on a scale of 1-5; higher scores represent a greater likelihood of recommending NDURE.

Time frame:
3 months
Reported as:
Mean · score on a scale
NDURE Program Evaluation Scale Score: Likelihood to Recommend
score on a scaleNDURE
NDURE Program Evaluation Scale Score: Likelihood to Recommend4.79 ± 0.58

Adverse events

Collected over From accrual in the study (at the initial surgical consultation) to the end of the study of the study for each participant (at the start of adjuvant radiation therapy). This time period is variable for participants but on average is approximately 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NDURE1/15 (6.7%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)NDURE
Median65 (32 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)NDURE
Female5
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NDURE
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)NDURE
United States15
Health Insurance Coverage
Health Insurance Coverage(Participants)NDURE
Private6
Medicare6
Medicaid1
Self-pay2
Marital Status
Marital Status(Participants)NDURE
Married/current partner8
Single/separated/divorced/widowed7
Living Situation
Living Situation(Participants)NDURE
Spouse/partner7
Parents/siblings/children3
Self5
Highest Level of Education
Highest Level of Education(Participants)NDURE
High school graduate5
Some college4
College or graduate school6

7 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
09

References and documents

Study documents

  • Informed consent form · Jul 26, 2019
  • Protocol and statistical analysis plan · May 26, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04098458
Lead sponsor
Medical University of South Carolina
Collaborators
National Cancer Institute (NCI)
Responsible party
Evan Graboyes (Assistant Professor, Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina) — Principal investigator
First posted
Sep 23, 2019
Start date
Sep 12, 2019
Primary completion
Apr 14, 2020
Completion
Apr 14, 2020
Results posted
Mar 22, 2021
Last update
Mar 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion